Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2015
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The efficacy and safety of tyrosine kinase inhibitors in the treatment of advanced or metastatic chordoma: a single-arm meta-analysis.Neurosurgical review · 2025Pooled it
- Targeted Therapy for Chordoma: Key Molecular Signaling Pathways and the Role of Multimodal Therapy.Targeted oncology · 2021Pooled it
- Systemic Treatment of Advanced Chordoma With Molecular Targeted Therapies: A Large Multicentre European Retrospective Case Series.Cancer reports (Hoboken, N.J.) · 2026Article
- Immunotherapy and tyrosine kinase inhibitors in chordoma: a real-world data study from a European Reference Network on Rare Adult Solid Cancers member center.Frontiers in oncology · 2026Article
- Cucurbitacin B Exhibits Antitumor Effects on Chordoma Cells via Disruption of Brachyury.International journal of molecular sciences · 2025Article
- Latest Developments in Targeted Biological Therapies in the Management of Chordoma and Chondrosarcoma.Global spine journal · 2025Article
- Immunologic and Targeted Molecular Therapies for Chordomas: A Narrative Review.Journal of clinical medicine · 2024Review
- Chordoma Genetic Aberrations and Targeted Therapies Panorama: A Systematic Literature Review.Journal of clinical medicine · 2024Review
- N6-methyladenosine-modified circTEAD1 stabilizes Yap1 mRNA to promote chordoma tumorigenesis.Clinical and translational medicine · 2024Article
- Integrated Molecular and Histological Insights for Targeted Therapies in Mesenchymal Sinonasal Tract Tumors.Current oncology reports · 2024Review
- Review
- Activity of pemetrexed in pre-clinical chordoma models and humans.Scientific reports · 2023Article
- Regorafenib for the Treatment of Sarcoma.Current treatment options in oncology · 2022Review
- Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma.Cell discovery · 2022Article
- Single-cell transcriptome profiling reveals intra-tumoral heterogeneity in human chordomas.Cancer immunology, immunotherapy : CII · 2022Article
- Cervical Paraspinal Chordoma: A Literature Review with a Novel Case Report.Journal of clinical medicine · 2022Article
- Management of Unresectable Localized Pelvic Bone Sarcomas: Current Practice and Future Perspectives.Cancers · 2022Review
- Challenges of Systemic Therapy Investigations for Bone Sarcomas.International journal of molecular sciences · 2022Review
- Personalized chordoma organoids for drug discovery studies.Science advances · 2022Article
- Advancement of PI3 Kinase Inhibitor Combination Therapies for PI3K-Aberrant Chordoma.Journal of neurological surgery. Part B, Skull base · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is no consensual treatment of locally advanced or metastatic chordomas. PATIENTS AND
methodsWe conducted a multicenter, open-label, uncontrolled phase II trial of sorafenib (800 mg/day). The primary end point was the 9-month progression-free rate according to RECIST 1.1. All patients had documented progressive disease at the time of study entry.
resultsTwenty-seven patients were enrolled between May 2011 and January 2014. The median age was 64 (range, 30-86) years. There were 17 men and 10 women. Twelve patients had been previously treated with chemotherapy and molecularly targeted agents. The maximum toxicity grade per patient was grade 3 in 21 cases (77.8%) and grade 4 in 4 cases (14.8%). Sorafenib provided an intent-to-treat best objective response of 1/27 [3.7%; 95% confidence interval (CI) 0.1% to 19.0%], a 9-month progression-free rate of 73.0% (95% CI 46.1-88.0) and a 12-month overall survival rate of 86.5% (95% CI 55.8-96.5). Survival curves were similar in pretreated and not pretreated patients. DISCUSSION: Additional clinical trials further exploring sorafenib as a treatment of locally advanced or metastatic chordomas are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.